- Home
- NMS vs CYPH Comparison
NMS vs CYPH Comparison
Compare NMS & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMS | CYPH |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.1M | 73.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NMS | CYPH |
|---|---|---|
| Price | $12.27 | $0.99 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.5K | ★ 4.7M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.07 | $0.50 |
| 52 Week High | $12.49 | $3.70 |
Technical Indicators
Market Signals| Indicator | NMS | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 55.14 | 46.80 |
| Support Level | $11.70 | $0.88 |
| Resistance Level | $12.49 | $1.08 |
| Average True Range (ATR) | 0.18 | 0.15 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 59.46 | 12.79 |
Price Performance
Historical ComparisonAbout NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About CYPH Cypherpunk Technologies Inc.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.